Rarely a day goes by without President Joe Biden mentioning insulin prices. He has been advocating for a $35 price cap on insulin for Americans on Medicare, making it a central theme in his speeches and campaign efforts. However, the impact of this initiative is more nuanced than it may seem.
While Biden's focus on insulin prices aims to highlight his commitment to healthcare, experts suggest that the actual benefits to eligible individuals might be overstated. Many of those benefiting from the price cap were already receiving discounted insulin or were existing Biden supporters. Additionally, individuals without Medicare or private health insurance are not covered by the reduced prices.
